New pill trial aims to outperform chemo for tough lung cancers
NCT ID NCT06956001
Summary
This study is comparing a new daily pill called firmonertinib against standard platinum-based chemotherapy for people with advanced non-small cell lung cancer (NSCLC) who have specific genetic changes (EGFR PACC or L861Q mutations). The goal is to see if the pill is more effective at controlling the cancer and has fewer side effects. About 300 adults who have not yet received treatment for their advanced cancer will be randomly assigned to receive either the pill or chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Tumor Hospital
RECRUITINGShandong, Jinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.